COMPASS Pathways plc

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Consensus

—

Average target

$15.00

Implied upside

—

Analysts

—

Why Is CMPS Flat Today?

COMPASS Pathways shares are essentially unchanged, down just $0.01 (0.07%), as the company continues advancing its psilocysin-assisted therapy programs through clinical initiatives and healthcare provider education. Recent activity suggests CMPS is maintaining momentum in Phase 3 trials and market development, though investor sentiment remains cautiously optimistic without major catalysts.

Bottom line: COMPASS Pathways remains in a holding pattern with neutral price action, as the market has largely priced in current Phase 3 clinical progress while awaiting regulatory decisions and meaningful revenue catalysts. Investors should monitor Phase 3 trial outcomes, FDA feedback, and commercial execution metrics closely, as the company's valuation leaves limited margin for error on key milestones.